1 tency greater than that of many conventional antitubercular agents.

2 ntify small molecule inhibitors as potential antitubercular agents.

3 igase) is a key target for the design of new antitubercular agents.

4            This makes the discovery of novel antitubercular agents a cogent priority.

5 -carboxamide analogue, 3, as a highly potent antitubercular agent, and the subsequent chemical modifi

6 alues lower than those of the most prominent antitubercular agents currently in use.

7 re a promising class of potent and selective antitubercular agents, if the metabolic liability can be

8                                          The antitubercular agent isoniazid can be activated by Mycob

9 icals found with KatG, while the less potent antitubercular agent nicotinic acid hydrazide produced t

10 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of

11 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of

12  (Sal-AMS) is a prototype for a new class of antitubercular agents that inhibit the aryl acid adenyla

13 red the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notabl